Balanced news tone
News Sentiment
ZLAB sentiment intelligence
Zai Lab Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
81/100 classification confidence.
directly relevant articles
high-authority source matches
+7.2% over one week, +20.0% over four weeks, trend inactive, and near fair-value range.
Director adds Zai Lab (ZLAB) ADS under pre-set Rule 10b5-1 plan
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Director adds Zai Lab (ZLAB) ADS under pre-set Rule 10b5-1 plan
Zai Lab Ltd director Richard Gaynor purchased 1,736 American Depositary Shares (ADS) on July 1, 2026, at $19.05 per ADS through an open-market transaction. This purchase was pre-scheduled under a Rule 10b5-1 trading plan adopted on December 16, 2025. Following the transaction, Ga
- Tone
- Positive 65/100
- Event
- Market update
- Published
- 06 Jul 2026 20:40
- Source
- Stock Titan
Zai Lab (ZLAB) CEO Du Ying gains ADSs from RSU awards and tax withholding
Zai Lab Ltd's CEO, Du Ying, engaged in compensation-related equity activity involving American Depositary Shares (ADSs) and Restricted Share Units (RSUs) on July 1–2, 2026. She acquired 29,048 ADSs through RSU exercises and had 11,431 ADSs withheld to cover tax obligations. Addit
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 20:40
- Source
- Stock Titan
Zai Lab (ZLAB) CEO sells ADS to cover taxes after RSU vesting
Zai Lab Ltd's Chairperson & CEO, Du Ying, reported routine equity compensation activity involving American Depositary Shares (ADSs). Du Ying exercised Restricted Share Units (RSUs) for 17,970 ADSs and subsequently sold 7,026 ADSs at $18.534 each to cover tax obligations. After th
- Tone
- Negative 40/100
- Event
- Market update
- Published
- 01 Jul 2026 20:40
- Source
- Stock Titan
Form 144 Zai Lab Ltd For: 30 June By Investing.com
This article announces the filing of Form 144 for Zai Lab Ltd for the period ending June 30. It provides a brief update on this specific financial filing, without offering further details on the content of the form. The article is very concise and primarily serves as a notificati
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 08:40
- Source
- Investing.com Nigeria
ZLAB (NASDAQ: ZLAB) insider resale planned on 06/29/2026; recent ADS sales reported
A ZLAB Form 144 filing reports a proposed resale of American Depositary Shares (ADS) linked to a Restricted Stock Vesting event scheduled for June 29, 2026. The filing also discloses multiple recent dispositions of ADS by an insider, Ying Du, between April 2, 2026, and June 26, 2
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 19:13
- Source
- Stock Titan
Zai Lab (ZLAB) legal chief settles RSUs, sells ADSs for taxes
Zai Lab's Chief Legal Officer, Edmondson Frazor Titus III, settled 14,600 Restricted Share Units (RSUs) into American Depositary Shares (ADSs) on June 25, 2026, as part of his compensation vesting schedule. The following day, 4,103 of these ADSs were sold at an average price of $
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 08:10
- Source
- Stock Titan
Zai Lab (ZLAB) CEO sells ADSs after RSU vesting and tax cover
Zai Lab's Chairperson and CEO, Ying Du, sold 24,543 American Depositary Shares (ADSs) for $17.461 each on June 26, 2026, to cover tax obligations following the vesting of 58,800 Restricted Share Units (RSUs) on June 25, 2026. After these transactions, Du directly owns 1,192,840 A
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 21:09
- Source
- Stock Titan
Enterprise value to revenue forward of Zai Lab Ltd. – HKEX:9688
This article provides a financial metric, specifically the enterprise value to revenue forward, for Zai Lab Ltd., traded on the Hong Kong Exchange under the ticker HKEX:9688. It highlights that the market was closed and no trades were made at the time of the report. The content a
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Jun 2026 20:39
- Source
- TradingView
CFO equity transactions at Zai Lab (ZLAB) show RSU vesting and tax sale
Zai Lab's CFO, Yajing Chen, reported equity compensation activity where 6,250 Restricted Share Units (RSUs) vested into American Depositary Shares (ADSs). Subsequently, 2,264 of these ADSs were automatically sold to cover tax obligations. Following these transactions, Chen direct
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 20:09
- Source
- Stock Titan
ETFs Investing in Zai Lab Ltd. Sponsored ADR Stocks
This article lists various ETFs that include Zai Lab Ltd. Sponsored ADR stocks in their holdings. It provides detailed financial information for each ETF, such as market value, weight of Zai Lab shares, issuer, management style, focus, expense ratio, AUM, price changes, and histo
- Tone
- Positive 65/100
- Event
- Market update
- Published
- 29 Jun 2026 10:40
- Source
- TradingView
Price to earnings forward of Zai Lab Ltd. – HKEX:9688
The article provides information regarding the "Price to earnings forward" metric for Zai Lab Ltd. (HKEX:9688), a biotechnology company listed on the Hong Kong Exchange. It presents a specific value for this financial metric during an unspecified period and details its change and
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 28 Jun 2026 12:10
- Source
- TradingView
Zai Lab Ltd. Sponsored ADR Actuals & Estimates (NASDAQ:ZLAB)
This article provides an overview of Zai Lab Limited (NASDAQ: ZLAB) with a focus on its financial actuals, estimates, and analyst forecasts available on TradingView. It highlights where users can explore reported financial data, compare actual results with average, high, and low
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 28 Jun 2026 07:39
- Source
- TradingView
Zai Lab Ltd. Sponsored ADR Actuals & Estimates (GETTEX:1ZL)
This page on TradingView provides an overview of Zai Lab Ltd. Sponsored ADR (GETTEX:1ZL), focusing on its actual financial data and analyst estimates. Users can explore reported financial data across income statements, balance sheets, and cash flow statements, comparing actual re
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 28 Jun 2026 03:09
- Source
- TradingView
ZLAB (NASDAQ) director files to sell 2,264 ADS after vesting
Zai Lab Ltd (ZLAB) has filed a Form 144 to report a proposed sale of 2,264 American Depositary Shares (ADS) following the vesting of restricted stock on June 25, 2026. This notice also details previous ADS dispositions by Yajing Chen on April 2, 2026, and April 6, 2026, for 5,199
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 19:10
- Source
- Stock Titan
ZLAB (NASDAQ: ZLAB) Form 144 shows Ying Du ADS sales and vesting event
Zai Lab Ltd (ZLAB) has filed a Form 144 detailing insider sales of American Depositary Shares (ADS) by Ying Du. The filing indicates 24,543 ADS are to be sold for an associated dollar figure of $428,552.69, and also records past sales by Ying Du between April and May 2026. These
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 19:10
- Source
- Stock Titan
ZLAB (NASDAQ: ZLAB) director files Form 144 to sell 4,103 ADS on vesting
Zai Lab Ltd (NASDAQ: ZLAB) director filed a Form 144 to sell 4,103 American Depositary Shares (ADS) due to restricted stock vesting on June 25, 2026. This filing also details previous ADS dispositions by Frazor T. Edmondson on April 2, April 6, and May 14, 2026. The Form 144 is a
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 19:10
- Source
- Stock Titan
Zai Lab Ltd. Actuals & Estimates (HKEX:9688)
This article provides an overview of Zai Lab Ltd. (HKEX:9688) stock performance, financial estimates, and key metrics. It covers the current stock price, historical highs and lows, analyst forecasts, volatility, market capitalization, and upcoming earnings reports, offering a com
- Tone
- Negative 39/100
- Event
- Earnings
- Published
- 26 Jun 2026 19:10
- Source
- TradingView
Zai Lab Ltd. Actuals & Estimates (LS:A3DJSH)
This article provides financial actuals and estimates for Zai Lab Ltd. (A3DJSH), including its current stock price, analyst forecasts, historical highs and lows, market capitalization, and upcoming earnings reports. It details financial metrics like revenue, net income, and EBITD
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 08:09
- Source
- TradingView
Price to sales forward of Zai Lab Ltd. – HKEX:9688
This article provides access to the forward Price to Sales ratio for Zai Lab Ltd. (HKEX:9688) through the TradingView platform. It details how users can view this financial metric along with other financial information for the company. The page also outlines various features and
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 08:09
- Source
- TradingView
ZLAB/N Forecast — Price Target — Prediction for 2027
This article provides a price target forecast for Zai Lab Ltd. Sponsored ADR (ZLAB/N) for 2027 based on analysis from 13 analysts. The current price target is 579.34, with no specific maximum or minimum estimates provided, and includes sections for annual and quarterly EPS and re
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Jun 2026 19:42
- Source
- TradingView
Zai Lab (ZLAB) director Lis sells 7,040 ADS under 10b5-1 plan
Zai Lab Ltd director William Lis sold 7,040 American Depositary Shares (ADS) at $18.09 each in an open-market transaction, following a Rule 10b5-1 trading plan established on September 10, 2025. After the sale, Lis directly holds 50,437 ADS. Each ADS represents ten Ordinary Share
- Tone
- Negative 37/100
- Event
- Market update
- Published
- 24 Jun 2026 19:39
- Source
- Stock Titan
Zai Lab (ZLAB) director receives 22,371 ADS stock award, now holds 79,001 ADSs
Richard Gaynor, a director at Zai Lab (ZLAB), was granted 22,371 American Depositary Shares (ADSs) as a compensation award on June 17, 2026. This award increased his direct holdings to 79,001 ADSs. The granted shares are restricted and will fully vest on June 17, 2027, provided G
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 18:09
- Source
- Stock Titan
Zai Lab (ZLAB) director receives 22,371 ADS equity award
Zai Lab Ltd director Nisa Leung was granted 22,371 American Depositary Shares (ADS) as compensation, boosting her direct holdings to 96,297 ADS. These restricted shares will fully vest on June 17, 2027, provided she continues her service on the board. The grant was reported in a
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 18:09
- Source
- Stock Titan
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Zai Lab Limited (NASDAQ:ZLAB) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Zai Lab Limited (NASDAQ:ZLAB) Analysts Are Cutting Their Estimates: Here's What You Need To Know
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 May 2026 07:00
- Source
- Market source
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source